| 1. |
Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase Ⅲ studies. J Hepatol, 2017, 67(5): 999-1008.
|
| 2. |
Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer, 2015, 136(6): 1458-1467.
|
| 3. |
中国医师协会肝癌专业委员会. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版). 临床肝胆病杂志, 2019, 35(4): 737-743.
|
| 4. |
程树群, 吴孟超, 陈汉, 等. 肝癌门静脉癌栓分型的影像学意义. 中华普通外科杂志, 2004, 19(4): 200-201.
|
| 5. |
Cheng SQ, Wu MC, Chen H, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. Hepatogastroenterology, 2007, 54(74): 499-502.
|
| 6. |
Chebaro A, Buc E, Durin T, et al. Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy?: a retrospective multicentric study. Ann Surg, 2021, 274(5): 874-880.
|
| 7. |
刘杰, 张成武, 洪德飞, 等. 腹腔镜前入路右半肝切除术治疗右肝巨大肿瘤. 中华普通外科杂志, 2017, 32(7): 581-584.
|
| 8. |
关斌颖, 杨国际, 刘天锡. 吲哚菁绿荧光染色技术在腹腔镜精准肝切除术中的应用体会. 腹腔镜外科杂志, 2020, 25(12): 919-924.
|
